or
forgot password

Improving the Therapeutic Ratio by Using Proton Beam Radiation Therapy for Patients With Stage IA-IIIBX (Bulky/Non-bulky) Hodgkin Lymphoma Involving the Mediastinum Following Standard Chemotherapy


Phase 2
6 Years
N/A
Open (Enrolling)
Both
Hodgkin Lymphoma

Thank you

Trial Information

Improving the Therapeutic Ratio by Using Proton Beam Radiation Therapy for Patients With Stage IA-IIIBX (Bulky/Non-bulky) Hodgkin Lymphoma Involving the Mediastinum Following Standard Chemotherapy


3 treatment plans will be created to deliver between a total of 21-45.6 Gy/CGE to the
planning target volume.

1. Proton Plan

2. Conventional Plan

3. IMRT Plan

The patient will then receive the radiation modality with the lowest body V4Gy/CGE


Inclusion Criteria:



- Confirmed "classic" Hodgkin lymphoma.

- Completed chemotherapy.

Exclusion Criteria:

- Prior radiotherapy.

- Prior or concurrent cancer other than non-melanomatous skin cancer.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the reduction of normal tissue exposed to greater than or equal to 4 Gy/CGE with use of proton therapy compared to photon therapy.

Outcome Time Frame:

Prior to starting radiation therapy

Safety Issue:

Yes

Principal Investigator

Bradford S Hoppe, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Florida Proton Therapy Institute

Authority:

United States: Institutional Review Board

Study ID:

UFPTI 0806 - HL01

NCT ID:

NCT00850200

Start Date:

August 2009

Completion Date:

July 2020

Related Keywords:

  • Hodgkin Lymphoma
  • Hodgkin Lymphoma, Proton Radiation
  • Hodgkin Disease
  • Lymphoma

Name

Location
University of Florida Proton Therapy Institute Jacksonville, Florida  32206